(Source: Xencor Inc) MONROVIA, Calif., March 19, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of A. Bruce Montgomery, M.D., to its Board of Directors. "Bruce is a clinical development expert with an impressive record of advancing promising drug programs through the clinic, including multiple drug approvals," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "His strong medical reputation coupled with his expertise in drug development is of...
↧